Status and phase
Conditions
Treatments
About
This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer.
Each cycle of treatment will be 4 weeks in length. Patients will be radiologically evaluated every 8 weeks for response. Patients will continue to receive study treatment until disease progression or unacceptable toxicity.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
To be eligible for the study, patients must fulfill all of the following criteria:
Exclusion criteria
Any of the following criteria will make the patient ineligible to participate in this study:
Primary purpose
Allocation
Interventional model
Masking
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal